Emerging Players in the Taiwan ADHD Medication Market | Top Companies & Insights 2026

Taiwan ADHD Medication Market Overview

According to 6Wresearch, the Taiwan ADHD Medication Market is growing, due to the change in clinical awareness from paediatric cases to increasing adult ADHD. The market is being driven by the robust national health insurance system that provides access to standardized pharmacologic interventions.

The market growth is being driven by a rising demand for extended-release formulations and non-stimulant alternatives. In addition, the introduction of digital mental health monitoring and enhanced diagnostic capabilities into Taiwan's advanced healthcare system is strengthening the provision of specialized therapies for the Central Nervous System (CNS).

Competitive Landscape

The competitive landscape of Taiwan ADHD medication industry is characterized by a balance of high-barrier branded stimulants and the rapid entry of high-quality local generics. Global innovators and local distributors often engage in strategic licensing agreements, leading to a diverse portfolio from long-acting methylphenidate to specialized neuro-supplements.

Below is a list of leading players operating in the Taiwan ADHD Medication Market:

1. Janssen Taiwan

Janssen Taiwan is a primary market leader, providing Concerta delivery system stimulant that remains a gold standard for sustained ADHD symptom management.

2. Novartis Taiwan

Novartis Taiwan is a major contributor to the CNS space, offering methylphenidate formulations, including immediate and long-acting options.

3. Takeda Taiwan

Takeda Taiwan maintains a dominant position in the ADHD segment through its specialized portfolio, including the non-stimulant Intuniv.

4. Viatris Taiwan

Viatris Taiwan provides a broad range of CNS medications and generic options, focusing on increasing patient access to high-quality neurological health treatments.

5. Orient EuroPharma (OEP)

OEP is a leading regional firm that specializes in the licensing and distribution of innovative ADHD treatments across the Taiwan market.

6. Lotus Pharmaceutical

Lotus focuses on high-barrier CNS generics and strategic in-licensing to provide cost-effective ADHD therapeutic options.

7. TTY Biopharm

TTY Biopharm is recognized for its advanced drug delivery technologies and its commitment to developing specialty CNS medications for the local market.

8. Standard Chem & Pharm

Standard Chem & Pharm is a key domestic player providing a variety of generic neuro-psychiatric medications and nerve health supplements.

9. Synmosa Biopharma

Synmosa focuses on niche therapeutic areas, including CNS and respiratory health, offering specialized pharmacological solutions tailored for the Taiwanese demographic.

10. Eli Lilly Taiwan

Eli Lilly Taiwan is a pioneer in the non-stimulant ADHD market, famously known for providing Strattera to patients who require alternatives to traditional stimulants.